Kidney transplant
Conditions
Interventions
Test group:Tocilizumab
Control group:Normal saline
Sponsors
Renji Hospital affiliated to Shanghai Jiao Tong University Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Subjects have given written consent to participate in the study 2. Renal transplantation in our hospital with regular follow-up 3. Patient sex not restricted, age = 18 years 4. Subjects previously known to have covid-19 must meet the following criteria: be asymptomatic for at least 1 month prior to initiation of screening 5. Donor kidneys receiving DCD, DBD, DBCD donations
Exclusion criteria
Exclusion criteria: 1) Multiple organ transplant recipients 2) Active viral infections such as BK virus (BKV) cytomegalovirus (CMV), EBV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection 3) Severe infection is occurring or has a history of infection requiring hospitalization 4) Active TB or latent TB 5) Liver function tests were abnormal: alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 2.0 × the upper limit of normal, bilirubin > 1.5 × the upper limit of normal 6) Neutropenia (< 2 x109 / L) or thrombocytopenia (< 100 x109 / L) 7) History of diverticulitis, inflammatory bowel disease or gastrointestinal perforation 8) Serious medical or psychiatric disorders that, according to the investigator, could interfere with participation in the study 9) Current or recent (within the last 3 months) participation in another clinical drug trial 10) Living kidney transplant recipients 11) Other conditions that the investigator considered unsuitable for enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scr;DGF; | — |
Secondary
| Measure | Time frame |
|---|---|
| cfDNA;Urine protein;complement;Inflammatory indicators; | — |
Countries
China
Contacts
Public ContactZhang Ming
Renji Hospital affiliated to Shanghai Jiao Tong University Medical College
Outcome results
None listed